What exactly did Benchmark change for the SGRY analyst rating on March 3, 2026?

Benchmark did not change the rating; it reiterated a **Buy** on March 3, 2026. The firm issued no new price target and kept its prior view after reviewing Q4 results.

Does the maintained SGRY analyst rating include a new price target?

No, Benchmark’s March 3, 2026 note did not publish a new SGRY price target. The commentary focused on results and the decision to keep the Buy rating.

How should investors interpret a maintained SGRY analyst rating?

A maintained SGRY analyst rating means the analyst sees no need to upgrade or downgrade after recent data. Investors should treat it as confirmation of the existing thesis rather than a fresh buy signal.

How does Meyka AI view the SGRY analyst rating?

Meyka AI rates SGRY with a grade of **B+**, reflecting analyst consensus, sector performance, and key financial metrics. This grade is informational and not investment advice.

Analyst Ratings

Benchmark Maintains Buy on Surgery Partners (SGRY) March 3, 2026

ByDanny Kontos March 4, 2026March 4, 2026

Benchmark maintained its Buy rating on Surgery Partners, Inc. (SGRY) on March 3, 2026. The note followed Q4 results and left the analyst view unchanged, a clear signal for investors watching coverage stability. The SGRY analyst rating appears defensive rather than aggressive, with no price target disclosed in the bulletin. Benchmark’s call coincided with a reported 6.67% ($0.87) move since the prior mention, showing modest market sensitivity to the reiteration. We use Meyka AI data to track how this SGRY analyst rating fits into broader coverage trends.